Genetic mechanisms of resistance to protease inhibitors and entry inhibitors

HIV Clinical Trials

Volumn 3, Issue 3, 2002, Pages 249-257

  Soriano, Vincent ^a   de Mendoza, Carmen ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Drug resistance; Entry inhibitors; HIV; Protease inhibitors

Indexed keywords

AMPRENAVIR; GAG PROTEIN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RECEPTOR;

ANTIVIRAL ACTIVITY; CODON; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; GENE FUSION; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURAL GENE; VIRAL GENETICS; VIRUS ADSORPTION; VIRUS ENVELOPE; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 0036307008     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/3C93-6MTH-9MAR-U0BE     Document Type: Review

References (67)

1. The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors
2. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure
3. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease
4. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials
5. Resistance to protease inhibitors
6. Resistance to HIV-1 protease inhibitors
7. Drug resistance during indinavir therapy is caused by mutations in the protease gene and its Gag substrate cleavage sites
8. Second Iocus involved in HIV-1 resistance to protease inhibitors
9. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors
10. Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase
11. Protease inhibitors: Resistance, cross-resistance, fitness and the choice of initial and salvage therapies
12. In vitro selection and characterization of HIV-1 isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease
13. Resistance during early virologic rebound on amprenavir plus zidovudine plus lamivudine triple therapy or amprenavir monotherapy in ACTG protocol 347
14. ABT-378, a highly potent inhibitor of HIV protease
15. In vitro selection and characterization of HIV-1 variants with increased resistance to ABT-378. A novel protease inhibitor
16. Genetic correlates of in vivo viral resistance to indinavir, a HIV-1 protease inhibitor
17. HIV-1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment
18. Impact of baseline polymorphisms in RT and protease on outcome of HAART in HIV-1-infected African patients
19. Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease, which retains susceptibility to protease inhibitors
20. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
21. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy AIDS
22. A preliminary evaluation of nelfinavir mesylate, an inhibitor of HIV-1 protease, to treat HIV infection
23. Resistance mutations in patients experiencing early failure with nelfinavir-containing triple combinations
24. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir
25. Replicative fitness of protease inhibitor-resistant mutants of HIV-1
26. Genetic correlates of virological response to an indinavir-containing salvage regimen in patients with nelfinavir failure
27. Sequencing of antiretroviral drugs
28. Phenotypic and genotypic analysis of clinical isolates reveals extensive protease inhibitor cross-resistance: A survey of over 6000 samples
29. Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants
30. Drug resistance and predicted virologic responses to HIV-1 protease inhibitor therapy
31. Functional correlates of insertion mutations in the protease gene of HIV-1 isolates from patients
32. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
33. HIV-1 viral background plays a major role in development of resistance to protease inhibitors
34. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during sub-optimal therapy
35. Retracing the evolutionary pathways of HIV-1 resistance to proteinase inhibitors. Virus fitness in the absence and in the presence of drug
36. Mutation patterns of the RT and protease genes in HIV-1-infected patients undergoing combination therapy: Survey of 787 sequences
37. HIV reverse transcriptase and protease sequence database: An expanded model integrating natural language text and sequence analysis
38. Identification of genotypic changes in HIV protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients
39. Quantitation of lopinavir resistance and cross-resistance and phenotypic contribution of mutations shared with other protease inhibitors
40. Analysis of mutational patterns associated with response to lopinavir/ritonavir in multiple protease inhibitor-experienced patients
41. Lopinavir resistance of amprenavir-selected, replication-impaired mutants of HIV
42. Differential impact of specific key mutations in HIV protease on phenotypic susceptibility to amprenavir and lopinavir
43. In vitro resistance profile of the HIV-1 protease inhibitor BMS-232632
44. Prevalence of the HIV protease inhibitor mutation N88S causing hypersensitivity to amprenavir
45. Drug resistance in patients experiencing early virological failure under a triple combination including indinavir
46. A mutation in HIV-1 protease, N88S, that causes in vitro hypersensitivity to amprenavir
47. HIV-1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo
48. Impact of HIV-1 protease, RT, cleavage site, and p6 mutations on the virologic response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs
49. Resistance to nucleoside analog reverse transcriptase inhibitors mediated by HIV-1 p6 protein
50. Polymorphisms in the p6/p6* of HIV-1 Gag are associated with hypersusceptibility to protease inhibitors
51. HIV-1 entry inhibitors
52. HIV resistance to entry inhibitors
53. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens
54. Selective employment of chemokine receptors as HIV-1 co-receptors determined by individual amino acids within the envelope V3 loop
55. HIV entry and its inhibition
56. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
57. The molecular target of bicyclams, potent inhibitors of HIV replication
58. Activity of different bicyclam derivatives against HIV depends on their interaction with the CXCR4 chemokine receptor
59. Variable sensitivity of CCR5-tropic HIV-1 isolates to inhibition by RANTES analogs
60. Involvement of both the V2 and V3 regions of the CCR5-tropic HIV-1 envelope in reduced sensitivity to macrophage inflammatory protein 1 alpha
61. The role of virus biological phenotype in HIV pathogenesis
62. Determinants of HIV-1 resistance to gp41-derived inhibitory peptides
63. Virus sensitivity to T-20 and T-1249 is independent of coreceptor usage
64. HIV-1 isolates from patients treated with T-20 are sensitive to the second-generation fusion inhibitor T-1249
65. Determination of coreceptor usage of HIV-1 from patient plasma samples by using a recombinant virus assay
66. Evaluating HIV-1 coreceptor usage and inhibitors of virus entry using recombinant virus assays
67. CD4+ and CD8+ T cell death during HIV infection in vitro